- Market Size (2026)
- USD 7.0 Bn
- Forecast (2036)
- USD 21.5 Bn
- CAGR (2026 to 2036)
- 11.8%
Immuno Oncology Assay Market Size, Market Forecast and Outlook By FMI
The immuno oncology assay market was valued at USD 6.3 billion in 2025. The market is set to reach USD 7.0 billion by 2026-end and grow at a CAGR of 11.8% between 2026-2036 to reach USD 21.5 billion by 2036. Reagents and Antibodies will dominate with a 37.6% share, while Checkpoint Inhibitors will lead with a 42.3% share.
Summary of the Immuno Oncology Assay Market
- Demand and Growth Drivers
- Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for immuno oncology assay products across hospitals and specialty care settings.
- Regulatory approvals for expanded clinical applications are broadening the addressable patient population and creating incremental demand in established and emerging treatment pathways.
- Reimbursement coverage expansion in East Asia and South Asia is reducing financial barriers to clinical adoption, enabling immuno oncology assay access in markets where volumes have been constrained.
- Product and Segment View
- Reagents and Antibodies account for 37.6% of the Product segment in 2026, supported by high clinical utilization.
- Checkpoint Inhibitors represent 42.3% of the Technology segment, reflecting established procedural protocols and broad clinical adoption.
- Lung Cancer accounts for 33.8% of the Indication segment, driven by concentrated demand in hospital and clinical settings.
- Geography and Competitive Outlook
- South Korea leads country-level growth at 15.2%, supported by expanding healthcare infrastructure and increasing treatment access.
- North America remains the largest regional market, with strong demand from established clinical and research institutions.
- THERMO FISHER SCIENTIFIC leads at an estimated 19.0% market share, supported by broad product portfolio and established institutional procurement relationships.
- Analyst Opinion
- The immuno oncology assay market is transitioning from a specialized clinical category into a more established treatment infrastructure segment as clinical evidence and reimbursement coverage expand.
- Adoption is shaped by the convergence of expanding clinical indications, reimbursement coverage growth, and the operational need for reliable treatment outcomes.
- Pricing pressure from hospital procurement teams and group purchasing organizations is compressing margins, shifting competitive differentiation toward clinical evidence, workflow integration, and regulatory-cleared product breadth.
- Companies that can combine broad indication coverage, validated clinical protocols, and institutional procurement relationships are positioned to capture growing procedural volume during the forecast period.
Key Takeaways, Market Size, and Forecast
- The Immuno Oncology Assay Market was valued at USD 6.30 billion in 2025.
- By 2036, the Immuno Oncology Assay Market is expected to be worth USD 21.49 billion.
- From 2026 to 2036, the market is projected to expand at a CAGR of 11.8%.
- The market is projected to create an incremental opportunity of USD 14.44 billion between 2026 and 2036.
- In 2026, Reagents and Antibodies is expected to account for 37.6% of the Product segment, driven by established clinical adoption and treatment protocol integration.
- South Korea (15.2%) and Japan (14.1%) are two of the fastest growing markets in the world.
Immuno Oncology Assay Market Definition
The immuno oncology assay market encompasses all commercially traded immuno oncology assay products categorized by product (reagents and antibodies, instruments, software, consumables and accessories), by technology (checkpoint inhibitors, cytokines & immunomodulators, monoclonal antibodies, other technologies), by indication (lung cancer, melanoma, colorectal cancer, other cancers), by end-user (hospitals, clinics, cancer research centers), by application (research applications, clinical diagnostics). Products are used across hospitals, specialty clinics, and research settings for clinical treatment and diagnostic applications.
Immuno Oncology Assay Market Inclusions
Market scope covers all commercially traded immuno oncology assay products categorized by product (reagents and antibodies, instruments, software, consumables and accessories), by technology (checkpoint inhibitors, cytokines & immunomodulators, monoclonal antibodies, other technologies), by indication (lung cancer, melanoma, colorectal cancer, other cancers), by end-user (hospitals, clinics, cancer research centers), by application (research applications, clinical diagnostics). Revenue is tracked from 2026 to 2036.
Immuno Oncology Assay Market Exclusions
The scope does not include general medical devices or therapeutic products unrelated to the specific immuno oncology assay product category, or components sold as raw materials without end-use specification.
Immuno Oncology Assay Market Research Methodology
- Primary Research: Interviews with clinical practitioners, hospital procurement teams, and device manufacturers across key markets in North America, Europe, and East Asia.
- Desk Research: Analysis of regulatory approval databases, reimbursement coding systems, clinical trial registries, and published treatment guidelines.
- Market Sizing and Forecasting: Bottom-up aggregation from procedural volumes and clinical utilization rates across primary segment and geographic categories, with regional adoption curves.
- Data Validation: Cross-checked quarterly against regulatory approval timelines, clinical registry data, and manufacturer revenue disclosures.
Why is the Immuno Oncology Assay Market Growing?
- Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for immuno oncology assay products across hospitals and specialty care settings.
- Regulatory approvals for expanded clinical applications are broadening the addressable patient population and creating incremental demand in established and emerging treatment pathways.
- South Korea leads with 15.2% growth, reflecting healthcare infrastructure expansion and increasing treatment access across hospital networks.
Clinical Adoption and Treatment Protocol Integration
Demand for immuno oncology assay products reflects the growing clinical evidence base and expanding treatment indications that are broadening the addressable patient population. Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for immuno oncology assay products across hospitals and specialty care settings. Clinical adoption is supported by published treatment protocols, favorable outcomes data, and growing physician familiarity with product capabilities across established and emerging indications.
Reimbursement and Access Expansion
Reimbursement coverage expansion across developed and emerging markets is reducing financial barriers to adoption. Established reimbursement frameworks in North America and Western Europe support procedural volumes, while progressive coverage expansion in East Asia and South Asia is opening new growth channels.
Competitive Dynamics and Pricing Pressure
High per-unit cost and the requirement for specialized clinical infrastructure limit adoption in resource-constrained healthcare settings and community-level facilities. Hospital procurement consolidation through group purchasing organizations is creating competitive pressure on device pricing, which is shifting manufacturer focus toward clinical differentiation, service contracts, and outcome-based value propositions.
Market Segmentation Analysis
- Reagents and Antibodies account for 37.6% of the Product segment in 2026, supported by high clinical utilization.
- Checkpoint Inhibitors represent 42.3% of the Technology segment, reflecting established procedural protocols and broad clinical adoption.
- Lung Cancer accounts for 33.8% of the Indication segment, driven by concentrated demand in hospital and clinical settings.
The immuno oncology assay market is segmented by product (reagents and antibodies, instruments, software, consumables and accessories), by technology (checkpoint inhibitors, cytokines & immunomodulators, monoclonal antibodies, other technologies), by indication (lung cancer, melanoma, colorectal cancer, other cancers), by end-user (hospitals, clinics, cancer research centers), by application (research applications, clinical diagnostics).
Insights into the Reagents and Antibodies Product Segment
Reagents and Antibodies account for 37.6% of the Product segment in 2026. Demand is concentrated in clinical settings where established treatment protocols and procedural infrastructure support regular utilization. The category maintains its leading position through broad clinical applicability and favorable cost-effectiveness relative to alternatives.
Procurement is shaped by institutional purchasing agreements and volume-based pricing through hospital group purchasing organizations. Other categories within the product segment, including Instruments, Software, Consumables and Accessories, serve additional clinical applications and treatment pathways.
Insights into the Checkpoint Inhibitors Technology Segment
Checkpoint Inhibitors account for 42.3% of the Technology segment in 2026. Demand is concentrated in clinical settings where established treatment protocols and procedural infrastructure support regular utilization. The category maintains its leading position through broad clinical applicability and favorable cost-effectiveness relative to alternatives.
Procurement is shaped by institutional purchasing agreements and volume-based pricing through hospital group purchasing organizations. Other categories within the technology segment, including Cytokines & Immunomodulators, Monoclonal Antibodies, Other Technologies, serve additional clinical applications and treatment pathways.
Immuno Oncology Assay Market Drivers, Restraints, and Opportunities
- Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for immuno oncology assay products across hospitals and specialty care settings.
- High per-unit cost and the requirement for specialized clinical infrastructure limit adoption in resource-constrained healthcare settings and community-level facilities.
- Expansion of clinical evidence into new indications represents a structural growth opportunity, as each validated application increases the addressable patient base.
The immuno oncology assay market grows on the back of expanding clinical indications, reimbursement coverage gains, and infrastructure investment in treatment delivery. High per-unit costs and infrastructure requirements constrain adoption in resource-limited settings.
Clinical Indication and Procedural Volume Growth
Rising disease prevalence and expanding treatment indications are generating sustained procedural demand for immuno oncology assay products across hospitals and specialty care settings.
Cost and Infrastructure Constraints
High per-unit cost and the requirement for specialized clinical infrastructure limit adoption in resource-constrained healthcare settings and community-level facilities.
Reimbursement and Access Drivers
Reimbursement coverage expansion in East Asia and South Asia is reducing financial barriers to clinical adoption, enabling immuno oncology assay access in markets where volumes have been constrained.
Geographic Expansion Opportunity
Healthcare infrastructure investment in China, India, and other emerging markets is expanding the installed base of clinical equipment and trained specialists, creating new procedural volume for immuno oncology assay products.
Analysis of Immuno Oncology Assay Market By Key Countries
.webp "Top Country Growth Comparison Immuno Oncology Assay Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| South Korea | 15.2% |
| Japan | 14.1% |
| UK | 13.9% |
| China | 13.3% |
- South Korea leads at 15.2% CAGR, reflecting expanding healthcare infrastructure and increasing treatment access.
- Japan at 14.1% sustains growth through established clinical programs and expanding reimbursement coverage.
- UK at 13.9% shows growth through established clinical programs and expanding reimbursement coverage.
- China at 13.3% shows growth through established clinical programs and expanding reimbursement coverage.
The global immuno oncology assay market is projected to grow at a CAGR of 11.8% from 2026 to 2036. Growth rates vary by country based on healthcare infrastructure capacity, reimbursement coverage, clinical adoption patterns, and disease prevalence.
Demand Outlook for Immuno Oncology Assay Market in South Korea
South Korea is projected to grow at 15.2% through 2036. Growth is shaped by expanding hospital infrastructure, increasing clinical adoption, and progressive reimbursement coverage for immuno oncology assay products.
- Hospital infrastructure expansion enables increased procedural capacity.
- Reimbursement coverage expansion supports broader patient access.
- Growing specialist training programs support adoption in secondary care settings.
Future Outlook for Immuno Oncology Assay Market in Japan
Japan is projected to grow at 14.1% through 2036. Growth is shaped by expanding hospital infrastructure, increasing clinical adoption, and progressive reimbursement coverage for immuno oncology assay products.
- Hospital infrastructure expansion enables increased procedural capacity.
- Reimbursement coverage expansion supports broader patient access.
- Growing specialist training programs support adoption in secondary care settings.
Opportunity Analysis of Immuno Oncology Assay Market in UK
UK is projected to grow at 13.9% through 2036. Growth is shaped by expanding hospital infrastructure, increasing clinical adoption, and progressive reimbursement coverage for immuno oncology assay products.
- Established clinical programs maintain steady procedural volumes.
- Reimbursement coverage expansion supports broader patient access.
- Growing specialist training programs support adoption in secondary care settings.
In-depth Analysis of Immuno Oncology Assay Market in China
China is projected to grow at 13.3% through 2036. Demand is supported by healthcare modernization, growing specialist availability, and increasing treatment access for immuno oncology assay products.
- Established clinical programs maintain steady procedural volumes.
- Institutional procurement channels sustain product demand.
- Growing specialist training programs support adoption in secondary care settings.
Competitive Landscape and Strategic Positioning
- THERMO FISHER SCIENTIFIC leads at an estimated 19.0% market share, supported by a broad product portfolio and established institutional procurement relationships.
- AGILENT TECHNOLOGIES and Sartorius AG compete on specialized product offerings and clinical evidence depth.
- NanoString Technologies and BIO-RAD LABORATORIES are expanding into emerging market segments.
THERMO FISHER SCIENTIFIC holds an estimated 19.0% share, supported by a comprehensive product portfolio, global manufacturing infrastructure, and established relationships with hospital procurement teams. AGILENT TECHNOLOGIES competes on clinical evidence depth, regulatory clearances, and product specialization.
The competitive landscape includes both large medical device companies with broad portfolios and specialized manufacturers focused on specific product categories or indications. Sartorius AG and NanoString Technologies serve specific clinical applications and regional markets.
Barriers to entry include regulatory approval requirements for medical devices, the need for clinical evidence from controlled trials, established hospital procurement relationships, and the requirement for manufacturing quality systems compliance. Strategic priorities center on expanding indication coverage, improving clinical outcomes data, and strengthening institutional procurement positions.
Key Companies in the Immuno Oncology Assay Market
Key global companies leading the immuno oncology assay market include:
- THERMO FISHER SCIENTIFIC, AGILENT TECHNOLOGIES, Sartorius AG hold leading positions with broad product portfolios, established regulatory clearances, and global institutional procurement networks.
- NanoString Technologies, BIO-RAD LABORATORIES, F. HOFFMANN-LA ROCHE LTD. compete on specialized product offerings, regional clinical expertise, and focused indication coverage.
- PERKINELMER, ILLUMINA, QIAGEN N.V., Charles River Laboratories serve emerging segments and specialized applications, representing potential growth competitors.
Competitive Benchmarking: Immuno Oncology Assay Market
| Company | Product Portfolio | Clinical Evidence | Institutional Access | Geographic Coverage |
|---|---|---|---|---|
| THERMO FISHER SCIENTIFIC | High | High | Strong | Global |
| AGILENT TECHNOLOGIES | High | High | Strong | Global |
| Sartorius AG | Medium | Medium | Moderate | Global |
| NanoString Technologies | Medium | Medium | Moderate | Global |
| BIO-RAD LABORATORIES | Medium | Medium | Moderate | Regional |
| F. HOFFMANN-LA ROCHE LTD. | Medium | Medium | Moderate | Regional |
| PERKINELMER | Low | Low | Low | Regional |
| ILLUMINA | Low | Low | Low | Regional |
| QIAGEN N.V. | Low | Low | Low | Regional |
| Charles River Laboratories | Low | Low | Low | Regional |
Source: Future Market Insights competitive analysis, 2026.
Key Players in the Immuno Oncology Assay Market
Major Global Players
- THERMO FISHER SCIENTIFIC
- AGILENT TECHNOLOGIES
- Sartorius AG
- NanoString Technologies
- BIO-RAD LABORATORIES
- F. HOFFMANN-LA ROCHE LTD.
Emerging Players/Startups
- PERKINELMER
- ILLUMINA
- QIAGEN N.V.
- Charles River Laboratories
Report Scope and Coverage
| Parameter | Details |
|---|---|
| Quantitative Units | USD 7.04 billion to USD 21.49 billion, at a CAGR of 11.8% |
| Market Definition | The immuno oncology assay market encompasses immuno oncology assay products used across clinical, research, and treatment settings. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | South Korea, Japan, UK, China, 30 plus countries |
| Key Companies Profiled | THERMO FISHER SCIENTIFIC, AGILENT TECHNOLOGIES, Sartorius AG, NanoString Technologies, BIO-RAD LABORATORIES, F. HOFFMANN-LA ROCHE LTD., PERKINELMER, ILLUMINA, QIAGEN N.V., Charles River Laboratories |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom-up and top-down methodology starting with verified procedural volume and clinical utilization data, projecting adoption velocity across segments and regions. |
Market Segmentation Analysis
Immuno Oncology Assay Market Segmented by Product:
- Reagents and Antibodies
- Instruments
- Software
- Consumables and Accessories
Immuno Oncology Assay Market Segmented by Technology:
- Checkpoint Inhibitors
- Cytokines & Immunomodulators
- Monoclonal Antibodies
- Other Technologies
Immuno Oncology Assay Market Segmented by Indication:
- Lung Cancer
- Melanoma
- Colorectal Cancer
- Other Cancers
Immuno Oncology Assay Market Segmented by End-User:
- Hospitals
- Clinics
- Cancer Research Centers
Immuno Oncology Assay Market Segmented by Application:
- Research Applications
- Clinical Diagnostics
Immuno Oncology Assay Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. World Health Organization. (2025). Global Health Observatory: Disease Burden and Treatment Access Statistics. WHO.
- 2. USA Food and Drug Administration. (2025). Medical Device Approvals and Clearances Database. FDA.
- 3. European Medicines Agency. (2024). Medical Device Regulation: Clinical Evidence and Performance Requirements. EMA.
- 4. Centers for Medicare and Medicaid Services. (2025). National Coverage Determinations for Medical Devices and Procedures. CMS.
- 5. National Institutes of Health. (2024). Clinical Trial Registry and Treatment Outcomes Database. NIH.
This bibliography is provided for reader reference.
This Report Answers
- Estimating the size of the immuno oncology assay market and revenue potential from 2026 to 2036.
- Segmentation by product (reagents and antibodies, instruments, software, consumables and accessories), by technology (checkpoint inhibitors, cytokines & immunomodulators, monoclonal antibodies, other technologies), by indication (lung cancer, melanoma, colorectal cancer, other cancers), by end-user (hospitals, clinics, cancer research centers), by application (research applications, clinical diagnostics).
- Regional insights across more than 30 markets including key growth countries.
- Analysis of clinical adoption trends, treatment protocols, and procedural dynamics.
- Assessment of the competitive landscape including leading manufacturers and emerging players.
- Identification of investment opportunities across clinical, research, and geographic expansion segments.
- Tracking of regulatory approvals, reimbursement changes, and clinical evidence developments.
- Delivery of data in PDF and Excel formats.
Frequently Asked Questions
What is the global market demand for Immuno Oncology Assay in 2026?
In 2026, the global immuno oncology assay market is expected to be worth USD 7.04 billion.
How big will the Immuno Oncology Assay Market be in 2036?
By 2036, the immuno oncology assay market is expected to be worth USD 21.49 billion.
How much is demand for Immuno Oncology Assay expected to grow between 2026 and 2036?
Between 2026 and 2036, the demand for immuno oncology assay is expected to grow at a CAGR of 11.8%.
Which Product is expected to lead in 2026?
Reagents and Antibodies are expected to account for 37.6% of the Product segment in 2026, supported by established clinical adoption and strong procedural demand.
What is causing demand to rise in South Korea?
South Korea is projected to grow at 15.2% through 2036, reflecting expanding healthcare infrastructure, increasing treatment access, and progressive reimbursement coverage.
What is causing demand to rise in Japan?
Japan is projected to grow at 14.1% through 2036, supported by healthcare modernization, growing specialist availability, and increasing treatment access.
What does this report mean by Immuno Oncology Assay Market definition?
The immuno oncology assay market includes immuno oncology assay products used across clinical, research, and treatment settings.
How does FMI make the Immuno Oncology Assay forecast and check it?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified procedural volume and clinical utilization data, and cross-referencing against regulatory approval databases, clinical registry data, and manufacturer disclosures.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Product
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Product , 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Product , 2026 to 2036
- Reagents and Antibodies
- Instruments
- Software
- Consumables and Accessories
- Reagents and Antibodies
- Y-o-Y Growth Trend Analysis By Product , 2021 to 2025
- Absolute $ Opportunity Analysis By Product , 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Technology
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Technology, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Technology, 2026 to 2036
- Checkpoint Inhibitors
- Cytokines & Immunomodulators
- Monoclonal Antibodies
- Other Technologies
- Checkpoint Inhibitors
- Y-o-Y Growth Trend Analysis By Technology, 2021 to 2025
- Absolute $ Opportunity Analysis By Technology, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Indication
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Indication, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Indication, 2026 to 2036
- Lung Cancer
- Melanoma
- Colorectal Cancer
- Other Cancers
- Lung Cancer
- Y-o-Y Growth Trend Analysis By Indication, 2021 to 2025
- Absolute $ Opportunity Analysis By Indication, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End-User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End-User, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End-User, 2026 to 2036
- Hospitals
- Clinics
- Cancer Research Centers
- Hospitals
- Y-o-Y Growth Trend Analysis By End-User, 2021 to 2025
- Absolute $ Opportunity Analysis By End-User, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Application
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Application, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Application, 2026 to 2036
- Research Applications
- Clinical Diagnostics
- Research Applications
- Y-o-Y Growth Trend Analysis By Application, 2021 to 2025
- Absolute $ Opportunity Analysis By Application, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Product
- By Technology
- By Indication
- By End-User
- By Application
- Competition Analysis
- Competition Deep Dive
- THERMO FISHER SCIENTIFIC
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- AGILENT TECHNOLOGIES
- Sartorius AG
- NanoString Technologies
- BIO-RAD LABORATORIES
- F. HOFFMANN-LA ROCHE LTD.
- PERKINELMER
- ILLUMINA
- QIAGEN N.V.
- Charles River Laboratories
- THERMO FISHER SCIENTIFIC
- Competition Deep Dive
- Assumptions & Acronyms Used
